Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+T-cell axis

Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation

(2015) Melanie R. Rutkowski et al.   CANCER CELL

TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity

(2015) D. Geng et al.   CANCER RESEARCH

The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity

(2015) Jeremy Dupaul-Chicoine et al.   IMMUNITY

TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses

(2015) Rebecca E. Riise et al.   JOURNAL OF IMMUNOLOGY

NK cells regulating T cell responses: mechanisms and outcome

(2015) Josh Crouse et al.   TRENDS IN IMMUNOLOGY

The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates

(2015) Vadim I. Krivokrysenko et al.   PLoS One

Abstract 4629: Tumor cells selected for resistance to an antibody-drug conjugate retain sensitivity to ADCs with modified linkers and payloads.

(2014) Xingzhi Tan et al.   CANCER RESEARCH

Flagellin-induced expression of CXCL10 mediates direct fungal killing and recruitment of NK cells to the cornea in response toCandida albicansinfection

(2014) Xiaowei Liu et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5

(2014) Kuzhuvelil B Harikumar et al.   NATURE IMMUNOLOGY

A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity

(2014) Nicholas D. Leigh et al.   PLoS One

Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice

(2014) Mohammad S. Hossain et al.   PLoS One

Chimeric Antigen Receptor Therapy for Cancer

(2013) David M. Barrett et al.   Annual Review of Medicine

Exploiting the curative potential of adoptive T-cell therapy for cancer

(2013) Christian S. Hinrichs et al.   IMMUNOLOGICAL REVIEWS

TLR-independent neutrophil-derived IFN-  is important for host resistance to intracellular pathogens

(2013) C. R. Sturge et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist

(2013) L. G. Burdelya et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice

(2012) H. Fan et al.   CLINICAL CANCER RESEARCH

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

(2012) Barbara Drobits et al.   JOURNAL OF CLINICAL INVESTIGATION

Cancer immunoediting by the innate immune system in the absence of adaptive immunity

(2012) Timothy O’Sullivan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Autocrine IFN-  Promotes Naive CD8 T Cell Differentiation and Synergizes with IFN-  To Stimulate Strong Function

(2012) J. M. Curtsinger et al.   JOURNAL OF IMMUNOLOGY

Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective Tumor-Specific Immune Responses

(2012) J. Garaude et al.   Science Translational Medicine

IRF-1 Expression Is Essential for Natural Killer Cells to Suppress Metastasis

(2011) A. Ksienzyk et al.   CANCER RESEARCH

Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth

(2011) Z. Cai et al.   CANCER RESEARCH

Toll-like Receptor 5 Agonist Protects Mice From Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy

(2011) Lyudmila G. Burdelya et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage

(2010) F A Carvalho et al.   Mucosal Immunology

TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses

(2009) Ildelfonso Vicente-Suarez et al.   IMMUNOLOGY LETTERS

Monotherapy with a Tumor-Targeting Mutant of S. typhimurium Inhibits Liver Metastasis in a Mouse Model of Pancreatic Cancer

(2009) Clinton Yam et al.   JOURNAL OF SURGICAL RESEARCH

Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-  and CXCR3 Ligands

(2008) M. Wendel et al.   CANCER RESEARCH

Toll-Like Receptor 5 Engagement Modulates Tumor Development and Growth in a Mouse Xenograft Model of Human Colon Cancer

(2008) Sang Hoon Rhee et al.   GASTROENTEROLOGY

Toll-Like Receptor 5-Deficient Mice Have Dysregulated Intestinal Gene Expression and Nonspecific Resistance to Salmonella-Induced Typhoid-Like Disease

(2008) M. Vijay-Kumar et al.   INFECTION AND IMMUNITY

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Christian Manegold et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5

(2008) Satoshi Uematsu et al.   NATURE IMMUNOLOGY

An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models

(2008) L. G. Burdelya et al.   SCIENCE